You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 26699 results
  1. Preclinical Studies Supporting Phase Ib Study of Minidystrophin Gene in AAV Vecto

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal intends to advance the regional delivery of a chimeric adeno-associated virus (rAAV)-based, highly-truncated dystrophin (minidystrophin) gene therapy for the treatment of Duchenes Muscular Dystrophy (DMD). Experiments focus on completing preclinical studies required to initiate, the also proposed, FDA recommended Phase Ib bridging study. The prop ...

    SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  2. Software as a Service Cardiovascular PACS Based on Web 2.0 Technologies

    SBC: HEART IMAGING TECHNOLOGIES, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Nearly two-thirds of all medical imaging procedures in the United States are performed in physician offices, yet few of these small healthcare providers can afford picture archiving and communication systems (PACS) needed to exchange these images with large hospitals. Without online access to previous imaging tests many procedures are repeated, leading to exces ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Inosine pro-drug: novel therapy for arthritis

    SBC: Inotek Pharmaceuticals Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is mediated by articular expression of pro-inflammatory cytokines and chemokines. We have discovered that the purine degradation product inosine exerts multiple anti-inflammatory and immunomodulatory effects via combined A2a and A3 agonism, resulting in suppressed expression of TNF-alpha, IL-1 beta, IL-12, MIP-lalpha, and IFN-gamma an ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  4. MyoRegulator: A non-invasive neuromodulation device for treatment of spasticity in stroke patients

    SBC: PATHMAKER MOBILITY CORP.            Topic: 101

    PROJECT SUMMARYABSTRACT Stroke affects overmillion patients in the U Swith an estimatedadditional cases of stroke occurring each yearOverof stroke survivors have spasticitya disorder of muscle tone that can cause striking impairments in functional movementPharmacologicalsurgical and physical treatments to manage spasticity haveat bestshort term efficacy and are confounded by side effectsIn this NI ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders

    SBC: Dicerna Pharmaceuticals, Inc.            Topic: 150

    Abstract Alcohol Use DisorderAUDis a chronic condition characterized by compulsive alcohol useloss of control over alcohol useand a negative emotional state when not using alcoholwith such use associated with a range of medicalpsychologicalsocialeconomicand personal problemsAUD is global and prevalentin a survey of overadults in the USAUD had amonth prevalence ofaffecting overmillion adults in the ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE

    SBC: SIBTECH, INC.            Topic: NCI

    The overall goal of this collaborative project between SibTech Inc PI Backer J and Johns Hopkins University PI Pomper M is clinical development of efficient and cost effective anti angiogenic Lu radiopharmaceutical scV Lu for VEGF receptor mediated targeting of angiogenic tumor vasculature Current very expensive anti angiogenic compounds induce transient regression of tumor vascula ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. IGF OT IGF I CLR AS A NEO ADJUVANT TREATMENT OPTION FOR TRIPLE NEGATIVE BREAST CANCER PERIOD OF PERFORMANCE

    SBC: Cellectar Biosciences, Inc.            Topic: NCI

    Poor prognosis of triple negative breast cancer TNBC is attributable to the absence of efficacious molecularly targeted neoadjuvant therapies Micrometastases contribute to poor prognosis by increasing recurrence rate Consequently an effective treatment option that is capable of targeting and sterilizing micrometastatic disease in patients with TNBC is warranted I CLR is proposed as ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Nitrogen Dioxide and Light-Absorbing Carbon Sensors for Personal Exposure Assessm

    SBC: AERODYNE RESEARCH INC            Topic: N/A

    DESCRIPTION (provided by applicant): This project addresses the need for the development of field deployable, sensors which provide real- time quantitative measurements at point-of-contact of airborne species that are injurious to human health - in this particular case, nitrogen dioxide and light-absorbing carbon. Nitrogen dioxide (NO2) is a highly toxic gas which when inhaled, causes the formati ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  9. Prevention of Delayed Cerebral Vasospasm Associated with Subarachnoid Hemorrhage

    SBC: HOPE PHARMACEUTICALS            Topic: N/A

    DESCRIPTION (provided by applicant): Hope Pharmaceuticals (Hope) is a Small Business that distributes a limited line of proprietary pharmaceuticals. In 2007, Hope licensed from the National Institutes of Health (NIH) exclusive, worldwide rights to two pending patent applications for recently discovered clinical uses for Sodium Nitrite, including in the area of neurology. Since it currently markets ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. A first-responder EEG device for seizure management in a nerve gas attack

    SBC: PERSYST DEVELOPMENT CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Nerve gas agents are seen by many as the poor man's atom bomb. As demonstrated in the March 1995 Tokyo subway attack, they can be used to inflict mass casualties in densely populated, confined air spaces. Medical management consists primarily of removing patients to an open air space. Atropine is administered and convulsions are titrated with benzodiazepines to ...

    SBIR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government